COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：4
|
作者：
Furneri, G. [1 ]
Santoni, L. [2 ]
Ricella, C. [2 ]
Prosperini, L. [3 ]
机构：
[1] EBMA Consulting, Melegnano, Italy
[2] Biogen, Milan, Italy
[3] Sapienza Univ, Dept Neurol & Psychiat 3, Rome, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2588
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM71
引用
收藏
页码：A695 / A695
页数：1
相关论文
共 50 条
  • [41] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024,
  • [42] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [43] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [44] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [45] COST-EFFECTIVENESS OF OCRELIZUMAB COMPARED TO FINGOLIMOD OR DMF IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CZECH REPUBLIC
    Dolezel, J.
    Havrdova, E. K.
    Skalicky, D.
    Pour, M.
    VALUE IN HEALTH, 2019, 22 : S282 - S282
  • [46] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS FINGOLIMOD IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN NORWAY
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Haines, P.
    Liu, Y.
    Bjornstad, B. M.
    Haukaas, F. S.
    VALUE IN HEALTH, 2016, 19 (07) : A433 - A433
  • [47] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [48] COST-EFFECTIVENESS OF OCRELIZUMAB COMPARED WITH DMT FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CZECH REPUBLIC
    Pour, M.
    Novak, J.
    Motylova, S.
    Skalicky, D.
    Krihova, K.
    Dolezel, J.
    VALUE IN HEALTH, 2023, 26 (06) : S273 - S273
  • [49] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [50] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    PharmacoEconomics, 2022, 40 : 323 - 339
12345